{"date": "2021-12-22 22:50:15.815000+00:00", "ticker": "III", "mrkt_info": {"open": 1405.5, "close": 1444.5}, "html": "<div class=\"storyContent\" lang=\"en\"><style type=\"text/css\">.storyContent * {border-color:inherit !important;outline-color:inherit !important;}</style><div class=\"tr-npp-lead\"><p>Allarity Therapeutics A/S, a clinical-stage biopharmaceutical company developing novel oncology therapeutics, has completed the USD20 million in PIPE investment, in which the company issued 20,000 shares of preferred stock (Preferred Stock) at USD1,000 per share and a common stock purchase warrant (the Warrant) to purchase 2,018,958 shares of common stock to 3i LP (3i Group Plc), a Delaware limited partnership</p><p>LifeSci Capital acted as placement agent for the PIPE Investment.</p></div><div class=\"tr-npp-body\"><p class=\"tr-npp-section-title\">Deal In Brief</p><div class=\"story-table-container\"><table class=\"story-basic-table\"><tbody><tr><td>Deal Value (US$ Million)</td><td>20</td> </tr><tr><td>Deal Type</td><td>Private Equity</td> </tr><tr><td>Sub-Category</td><td>DIRECT INVESTMENT</td> </tr><tr><td>Deal Status</td><td>Completed: 2021-12-21</td> </tr> </tbody> </table></div><p class=\"tr-npp-section-title\">Deal Participants</p><div class=\"story-table-container\"><table class=\"story-basic-table\"><tbody><tr><td>Target (Company)</td><td>Medical Prognosis Institute A/S</td> </tr><tr><td>Acquirer (Company)</td><td>3i Group plc</td> </tr> </tbody> </table></div><p class=\"tr-npp-section-title\">Deal Rationale</p><div class=\"story-table-container\"><table class=\"story-basic-table\"><tbody><tr><td>No. Shares Issued</td><td>20000</td> </tr> </tbody> </table></div><p><span>(Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Marketline shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon.)</span> </p></div><p class=\"line-break\"><br/></p><p class=\"tr-copyright\">Copyright \u00a9 2001 Marketline. All rights reserved.</p></div>"}